Download
new optimism for patients with cancer n.
Skip this Video
Loading SlideShow in 5 Seconds..
New optimism for patients with cancer PowerPoint Presentation
Download Presentation
New optimism for patients with cancer

New optimism for patients with cancer

246 Vues Download Presentation
Télécharger la présentation

New optimism for patients with cancer

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. New optimism for patients with cancer • As cancer therapy evolves, new regimens and novel agents that target specific cellular processes allow a more optimistic prognosis for many patients • Bortezomib and tipifarnib are two new targeted treatments for hematologic malignancies

  2. Bortezomib • A proteasome inhibitor • Has shown good efficacy as a single agent and in combination in patients • with relapsed multiple myeloma • as initial treatment, including prior to autologous stem cell transplantation • Has been studied as monotherapy and in combination with standard treatments, such as dexamethasone, chemotherapy, and with newer agents such as the IMiDs, thalidomide and lenalidomide • Is well-tolerated, including in combination

  3. Clinical course of multiple myeloma Survival (years) 0 1 2 3 4 5 Diagnosis to death 3–4 years • Relapsed disease • Transient response to therapy 1–2 years • Relapsed and refractory • Resistant to all therapy • Universally fatal 6–9 months

  4. b2 b1 Post- glutamylsite Trypticsite H b7 b3 N N H Bortezomib b6 b4 Chymo- trypticsite b5 O OH N B OH O N Bortezomib: a potent first-in-class proteasome inhibitor Dipeptidyl boronic acidderivative Cross-section of b-ring (reversible inhibitor of chymotryptic active site of proteasome  subunit) Janssen-Cilag 2003

  5. X X X Bortezomib

  6. Summary of bortezomib data in relapsed/refractory MM 1. Abstracts in Blood 2005;106 (ASH 2005) 2. Blood 2005;105:3058–65

  7. CR+PR 34% CR+PR 45% n is shown by the number on each bar Response to bortezomib by prognostic factor and line of treatment >1 prior treatment and MM refractory to prior treatment resulted in lower responses to bortezomib Richardson et al. ASCO 2005; Sonneveld et al. IMW 10, Sydney, 2005

  8. Bortezomib: higher response rates in second-line therapy than later therapy CR nCR PR 100 P=0.0035 80 P<0.0001 60 45 Proportion of patients (%) 40 34 26 32 20 13 21 0.5 nCR 23 6 7 13 0 6 2 6 Bortezomib Dex Bortezomib Dex 1 prior line of therapy >1 prior line of therapy Sonneveld et al. IMW 10, Sydney, 2005

  9. Single-agent bortezomib active in newly diagnosed MM • Well tolerated: safety profile similar to previous studies • Neuropathy frequently prevalent at baseline *Stem cells successfully harvested from 13 patients: 12 received transplants Richardson et al. Blood 2004;104:100a (abstract 336)Jagannath et al. Haematologica 2005;90(Suppl 1):148 (abstract P0.725)

  10. Bortezomib + dexamethasone in newly diagnosed MM Data available for 46/52 patients • Stem cell collection adequate for all patients (median CD34+ cells 6.7 x 106/kg; range 2–33); median 2 collections required (range 1–4) • Well tolerated: AEs mainly grade 1/2 • PN: 6% grade 3, 8% grade 2 • 1 grade 4 GI • Results form basis for IFM Phase III trial of bortezomib + Dex vs VAD Harousseau et al. Haematologica 2005;90(Suppl 1):148(abstract P0.724)

  11. Bortezomib combination protocols in previously untreated patients *VEL: Bortezomib – VELCADE® 1. Abstracts in Blood 2005;106 (ASH 2005) 2. Abstract in Blood 2004;104 (ASH 2004)

  12. 72% 85% 64% 70% 70% 60% 60% 45% 50% 50% 28% 40% 40% 24% 30% 30% 11% 13% 20% 20% 6% 6% 2% 10% 10% 0% 0% CR IF- CRIF+ PR MR SD CR IF- CR IF+ PR SD MPV response rates (n=53)Analysis of best response achieved so far 1st cycle MPV Best response: median 3 cycles Mateos et al. Blood 2005;106 (Abs 786) ASH 2005

  13. Adverse events from APEX (all patients) †Deaths within 30 days after last dose *69% of 310 patients on bortezomib reported symptoms of PN at baseline ** SUMMIT/CREST: PN ≥ grade 3, 13% Thrombocytopenia ≥ grade 3, 30% Richardson et al.N Engl J Med 2005;352:2487–98

  14. Tipifarnib • A specific inhibitor of farnesyltransferase • Clinical trials in patients with high-risk acute leukemias and myelodysplastic syndromes have demonstrated good efficacy with tipifarnib, even in patients with poor prognosis and elderly, poor-risk patients

  15. Oral formulation Potent and selective inhibitor of farnesylation Key enzyme involved in multiple tumor-promoting pathways Essential for the functioning of signal transduction cascades associated with cell proliferation Potent inhibitor of malignant cell line proliferation Cl Cl N H 2 N N O N Tipifarnib:targeted farnesyltransferase inhibitor

  16. Key enzyme in many pathways Farnesylated proteins Ras (H-, K-, N-) Rho (B,E) Lamins (A, B) Centromere-binding proteins Farnesyltransferase Blocking FTase has therapeutic potential

  17. Phase II trial of tipifarnib: efficacy Response confirmed 28 days after initial response Relapsed Refractory Total (n=135) (n=117) (n=252) CR 7 (5%) 4 (3%) 11 (4%) Confirmed CR 2 (1%) 1 (1%)  3 (1%) SD (>8 weeks) 8 (6%) 5 (4%) 13 (5%) Total 15 (11%) 9 (8%) 24 (10%) Harousseau et al. Presentedat ASH 2003

  18. Targeted therapy • Is among the most exciting new development in cancer treatment • Specifically attacks the malignancy for improved efficacy and overall safety • Underscores an important shift in the treatment paradigm for multiple myeloma and other hematologic malignancies – a shift from empirical chemotherapeutic regimens with significant side effects towards rational, targeted, effective therapies with improved tolerability